AbbVie Inc. 

ABBV Price

🌱 0d

What is AbbVie (ABBV) stock?

AbbVie Inc. is a global biopharmaceutical company formed on January 1, 2013 as a spin-off of Abbott Laboratories' research-based pharmaceutical business. AbbVie trades on the NYSE under the ticker ABBV. The portfolio is strongest in immunology (Skyrizi, Rinvoq, legacy Humira), oncology (Imbruvica, Venclexta), and aesthetics (Botox). On DropsTab, the tracked instrument is the ABBV ticker as a USDT-margined perpetual-futures derivative.

Is AbbVie Inc. a US company?

Yes. AbbVie is a US company headquartered in North Chicago, Illinois. AbbVie's US pharmaceutical sales run through FDA review, and clinical-trial outcomes plus regulatory approvals directly shape AbbVie's revenue. Generic competition and research and development costs also factor into results.

How is ABBV traded on crypto exchanges?

Per DropsTab data, ABBV perpetual futures trade on major derivatives venues: Binance Futures (ABBVUSDT), OKX (ABBV-USDT-SWAP), Bybit Futures (ABBVUSDT), and Gate.io Futures (ABBV_USDT), all verified USDT-margined markets. DropsTab records no spot and no decentralized-exchange pairs for ABBV, consistent with an equity-ticker derivative. Liquidity concentrates on top-tier centralized derivatives desks.

Do ABBV perpetual futures pay the AbbVie dividend?

AbbVie stock pays a quarterly dividend of $1.73 per share, $6.92 annualized, most recently declared on September 10, 2026. The payment belongs to NYSE shareholders of record. A perpetual futures position on ABBV delivers price exposure only: the contract pays no dividend and carries no share ownership, voting rights, or buyback claims. Traders seeking the dividend need the underlying stock.

Is ABBVx xStocks the same asset as the ABBV tracked here?

ABBVx is a tokenized AbbVie share issued by Backed Finance under the xStocks brand, live as a Solana SPL token. The ABBV instrument on this page is a different product: perpetual futures contracts on centralized venues, with no wrapper issuer and no on-chain contract. Tokenized-stock listings on Crypto.com and Robinhood are separate instruments as well. The three differ in custody, settlement, and shareholder rights.

Why is AbbVie buying Apogee Therapeutics?

AbbVie agreed to acquire Apogee Therapeutics for approximately $10.9 billion in cash at $135.11 per share, announced June 22, 2026. The deal closed on September 3, 2026. It brought APG777, a half-life-extended anti-IL-13 antibody designed as a longer-acting maintenance therapy for atopic dermatitis, deepening AbbVie's immunology pipeline as Humira biosimilar erosion continues. AbbVie trimmed its 2026 profit forecast after the announcement.

Does ABBV have a token supply or vesting schedule?

No. ABBV is common stock listed on the NYSE, so no token supply, emission schedule, allocation breakdown, vesting cliff, or unlock calendar applies. Dilution is the closest analogue to token inflation: AbbVie can issue new shares, for example to fund acquisitions, which dilutes existing holders. For a perpetual position, dilution shows up only as price movement.

What are the risks of trading ABBV perpetual futures?

The main risks sit on the leverage side. A perpetual position carries funding-rate costs and liquidation exposure, and a leveraged holder feels volatility around earnings and acquisition news more sharply than a stockholder. The corporate calendar drives the underlying price: quarterly results, FDA decisions, and the biosimilar erosion affecting Humira and Imbruvica all feed into it. ABBV on DropsTab trades only as a margined derivative.